

# Thomas Alured Faunce

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5634430/publications.pdf>

Version: 2024-02-01

93  
papers

1,535  
citations

471509

17  
h-index

315739

38  
g-index

95  
all docs

95  
docs citations

95  
times ranked

2179  
citing authors

#	ARTICLE	IF	CITATIONS
1	Citizens' Juries, Liquid Democracy and Legislative Reform of Australian Compulsory Insurance Schemes for Injury Compensation after Motor Vehicle Accidents. <i>Journal of Law &amp; Medicine</i> , 2019, 26, 571-582.	0.0	0
2	Australian Medical Professionals, National Security and Administrative Offshore Punishment of Asylum-Seekers: Regulatory Update Including the Medevac Legislation. <i>Journal of Law &amp; Medicine</i> , 2019, 26, 742-749.	0.0	0
3	Global Artificial Photosynthesis and Renewable Energy Storage and Policy for the Sustainocene. <i>Advanced Sustainable Systems</i> , 2018, 2, 1800035.	5.3	3
4	Mercury Pollution from Coal-Fired Power Plants: A Critical Analysis of the Australian Regulatory Response to Public Health Risks. <i>Journal of Law &amp; Medicine</i> , 2018, 26, 480-487.	0.0	1
5	Governing the Global Food System Towards the Sustainocene with Artificial Photosynthesis. , 2016, , 373-406.		0
6	NuCoal Resources Ltd v New South Wales: The mining industry and potential health impacts of investor-state dispute settlement in Australia. <i>Journal of Law &amp; Medicine</i> , 2016, 23, 801-12.	0.0	0
7	Australia's embrace of investor state dispute settlement: a challenge to the social contract ideal?. <i>Australian Journal of International Affairs</i> , 2015, 69, 595-609.	1.5	4
8	How the Australia-US free trade agreement compromised the pharmaceutical benefits scheme. <i>Australian Journal of International Affairs</i> , 2015, 69, 473-478.	1.5	4
9	Sustainable fuel, food, fertilizer and ecosystems through a global artificial photosynthetic system: overcoming anticompetitive barriers. <i>Interface Focus</i> , 2015, 5, 20150011.	3.0	5
10	Does the world need a global project on artificial photosynthesis?. <i>Interface Focus</i> , 2015, 5, 20150029.	3.0	2
11	AUSTRALIAN COMPETITION AND CONSUMER COMMISSION v ACN 117 372 915: SHOULD CONSUMER LAW REGULATE DOCTOR-PATIENT RELATIONS IN A CORPORATISED HEALTH CARE SYSTEM?. <i>Journal of Law &amp; Medicine</i> , 2015, 23, 55-66.	0.0	0
12	Human serum albumin binding to silica nanoparticles â€œ effect of protein fatty acid ligand. <i>Physical Chemistry Chemical Physics</i> , 2014, 16, 10157-10168.	2.8	14
13	Nanotechnology and Military Attacks on Photosynthesis. , 2014, , 175-190.		0
14	Nanotechnology in Japan: A route to energy security after Fukushima?. <i>Bulletin of the Atomic Scientists</i> , 2013, 69, 68-74.	0.6	4
15	Artificial photosynthesis as a frontier technology for energy sustainability. <i>Energy and Environmental Science</i> , 2013, 6, 1074.	30.8	284
16	Energy and environment policy case for a global project on artificial photosynthesis. <i>Energy and Environmental Science</i> , 2013, 6, 695.	30.8	264
17	Trials and tribulations in the removal of dextropropoxyphene from the Australian Register of Therapeutic Goods. <i>Medical Journal of Australia</i> , 2013, 199, 257-260.	1.7	2
18	Planetary medicine and the Waitangi Tribunal Whanganui River report: global health law embracing ecosystem as patients. <i>Journal of Law &amp; Medicine</i> , 2013, 20, 528-41.	0.0	6

#	ARTICLE	IF	CITATIONS
19	Disclosure of material risk as systems-error tragedy: Wallace v Kam (2013) 87 ALJR 648; [2013] HCA 19. Journal of Law & Medicine, 2013, 21, 53-65.	0.0	1
20	Exploring International Legal Governance of Global Solar Fuels. Procedia Engineering, 2012, 49, 10-14.	1.2	0
21	Towards a Global Solar Fuels Project-Artificial Photosynthesis and the Transition from Anthropocene to Sustainocene. Procedia Engineering, 2012, 49, 348-356.	1.2	14
22	Towards Global Artificial Photosynthesis (Global Solar Fuels): Energy, Nanochemistry, and Governance. Australian Journal of Chemistry, 2012, 65, 557.	0.9	10
23	Nano-Safety or Nano-Security? Reassessing Europe's Nanotechnology Regulation in the Context of International Security Law. European Journal of Risk Regulation, 2012, 3, 416-421.	1.2	2
24	Governing Planetary Nanomedicine: Environmental Sustainability and a UNESCO Universal Declaration on the Bioethics and Human Rights of Natural and Artificial Photosynthesis (Global Solar Fuels and) Tj ETQq0 0 0 rgtB/Overlook 10 Tf 5	0.0	0
25	Re Edwards (2011) 4 ASTLR 392: who owns a dead man's sperm?. Journal of Law & Medicine, 2012, 19, 479-89.	0.0	0
26	Balancing public health, trade and intellectual monopoly privileges: recent Australian IP legislation and the TPPA. Journal of Law & Medicine, 2012, 20, 280-94.	0.0	3
27	The Trans-Pacific Partnership Agreement: challenges for Australian health and medicine policies. Medical Journal of Australia, 2011, 194, 83-86.	1.7	16
28	International Conference: Towards Global Artificial Photosynthesis: Energy, Nanochemistry and Governance (GAP I). Photosynthesis Research, 2011, 107, 287-287.	2.9	0
29	What makes a real man? Gender norms and Western Australia v. AH [2010] WASCA 172. Journal of Law & Medicine, 2011, 18, 478-97.	0.0	0
30	Freedom of information applications as an "evergreening" tactic: Secretary, Department of Health and Ageing v iNOVA Pharmaceuticals (Australia) Pty Ltd (2010) 191 FCR 573; [2010] FCA 1442. Journal of Law & Medicine, 2011, 19, 43-52.	0.0	1
31	Condlyff v North Staffordshire Primary Care Trust: can human rights redress inequities in United Kingdom and Australian cost-containment-driven health care reforms?. Journal of Law & Medicine, 2011, 19, 255-71.	0.0	2
32	Global artificial photosynthesis project: a scientific and legal introduction. Journal of Law & Medicine, 2011, 19, 275-81.	0.0	2
33	Exploring the safety of nanoparticles in Australian sunscreens. International Journal of Biomedical Nanoscience and Nanotechnology, 2010, 1, 87.	0.1	22
34	A methodological framework of preparing economic evidence for selection of medicines in the Chinese setting. Journal of Evidence-Based Medicine, 2010, 3, 156-161.	1.8	0
35	Impact of the Australia-US Free Trade Agreement on Australian Medicines Regulation and Prices. Journal of Generic Medicines, 2010, 7, 18-29.	0.2	16
36	Nanosilver and global public health: international regulatory issues. Nanomedicine, 2010, 5, 617-632.	3.3	111

#	ARTICLE	IF	CITATIONS
37	Reducing injustice from recent legislation subsidising insurance and restricting civil liability?: Baker-Morrison v NSW [2009] Aust Torts Reports 81-999; Amaca Pty Ltd v Novek [2009] Aust Torts Reports 82-001. Journal of Law & Medicine, 2010, 17, 729-35.	0.0	0
38	The Vioxx pharmaceutical scandal: Peterson v Merke Sharpe & Dohme (Aust) Pty Ltd (2010) 184 FCR 1. Journal of Law & Medicine, 2010, 18, 38-49.	0.0	10
39	The High Court's lost chance in medical negligence: Tabet v Gett (2010) 240 CLR 537. Journal of Law & Medicine, 2010, 18, 275-83.	0.0	0
40	Recovering fraudulent claims for Australian federal expenditure on pharmaceuticals and medical devices. Journal of Law & Medicine, 2010, 18, 302-15.	0.0	3
41	Safety of nanoparticles in sunscreens. Medical Journal of Australia, 2009, 190, 463-463.	1.7	6
42	Normative Foundations of Technology Transfer and Transnational Benefit Principles in the UNESCO Universal Declaration on Bioethics and Human Rights. Journal of Medicine and Philosophy, 2009, 34, 296-321.	0.8	14
43	Hearing Australian Aboriginal voices on neglect and sustainability. Medical Humanities, 2009, 35, 4-5.	1.2	3
44	Republication: In That Case. Journal of Bioethical Inquiry, 2009, 6, 139-139.	1.5	0
45	Policy challenges of nanomedicine for Australia's PBS. Australian Health Review, 2009, 33, 258.	1.1	11
46	New Australian federal organ and tissue donation legislation: enhanced transplant services but no "opt-out". Journal of Law & Medicine, 2009, 16, 590-4.	0.0	0
47	Recent legal developments and the authority of the Australian Therapeutic Goods Administration. Journal of Law & Medicine, 2009, 16, 764-9.	0.0	3
48	Australian professional practice bodies and the tort of negligent investigation. Journal of Law & Medicine, 2009, 17, 46-51.	0.0	0
49	Sunscreen Safety: The Precautionary Principle, The Australian Therapeutic Goods Administration and Nanoparticles in Sunscreens. NanoEthics, 2008, 2, 231-240.	0.8	56
50	In That Case. Journal of Bioethical Inquiry, 2008, 5, 323-324.	1.5	0
51	Decision-analytical modelling in health-care economic evaluations. European Journal of Health Economics, 2008, 9, 313-323.	2.8	47
52	Bilateral trade agreements as drivers of national and transnational benefit from health technology policy: implications of recent US deals for Australian negotiations with China and India. Australian Journal of International Affairs, 2008, 62, 196-213.	1.5	7
53	Toxicological and public good considerations for the regulation of nanomaterial-containing medical products. Expert Opinion on Drug Safety, 2008, 7, 103-106.	2.4	29
54	Three Proposals for Rewarding Novel Health Technologies Benefiting People Living in Poverty. A Comparative Analysis of Prize Funds, Health Impact Funds and a Cost-Effectiveness/Competitive Tender Treaty. Public Health Ethics, 2008, 1, 146-153.	1.0	13

#	ARTICLE	IF	CITATIONS
55	Integrated research into the nanoparticleâ€“protein corona: a new focus for safe, sustainable and equitable development of nanomedicines. <i>Nanomedicine</i> , 2008, 3, 859-866.	3.3	51
56	Supervising junior doctors and "on-call" responsibilities: <i>Brus v Australian Capital Territory; Greater Southern Area Health Service v Angus</i> . <i>Journal of Law &amp; Medicine</i> , 2008, 15, 513-9.	0.0	0
57	Medical professionals convicted of accessing child pornographyâ€“presumptive lifetime prohibition on paediatric practice? <i>Health Care Complaints Commission v Wingate</i> . <i>Journal of Law &amp; Medicine</i> , 2008, 15, 704-13.	0.0	1
58	<i>Selim v Lele</i> and the civil (industrial) conscription prohibition: constitutional protection against federal legislation controlling or privatising Australian public hospitals. <i>Journal of Law &amp; Medicine</i> , 2008, 16, 36-48.	0.0	0
59	New forms of evergreening in Australia: misleading advertising, enantiomers and data exclusivity: <i>Apotex v Servier</i> and <i>Alphapharm v Lundbeck</i> . <i>Journal of Law &amp; Medicine</i> , 2008, 16, 220-32.	0.0	2
60	<i>University of Western Australia v Gray</i> : an academic duty to commercialise research?. <i>Journal of Law &amp; Medicine</i> , 2008, 16, 419-25.	0.0	0
61	'Linkage' pharmaceutical evergreening in Canada and Australia. <i>Australia and New Zealand Health Policy</i> , 2007, 4, 8.	2.2	22
62	Challenges for Australia's Bio/Nanopharma Policies: trade deals, public goods and reference pricing in sustainable industrial renewal. <i>Australia and New Zealand Health Policy</i> , 2007, 4, 9.	2.2	5
63	Balancing intellectual monopoly privileges and the need for essential medicines. <i>Globalization and Health</i> , 2007, 3, 4.	4.9	8
64	Nanotherapeutics: new challenges for safety and costâ€“effectiveness regulation in Australia. <i>Medical Journal of Australia</i> , 2007, 186, 189-191.	1.7	23
65	Reference pricing for pharmaceuticals: is the Australiaâ€“United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme?. <i>Medical Journal of Australia</i> , 2007, 187, 240-242.	1.7	14
66	Drug price reforms: the new F1â€“F2 bifurcation. <i>Australian Prescriber</i> , 2007, 30, 138-140.	1.0	9
67	Abandoning the common law: medical negligence, genetic tests and wrongful life in the Australian High Court. <i>Journal of Law &amp; Medicine</i> , 2007, 14, 469-77.	0.0	1
68	The <i>Carhart</i> case and late-term abortions -- what's next in Australia?. <i>Journal of Law &amp; Medicine</i> , 2007, 15, 23-9.	0.0	1
69	Researching safety and cost-effectiveness in the life cycle of nanomedicine. <i>Journal of Law &amp; Medicine</i> , 2007, 15, 128-35.	0.0	8
70	<i>Carney v Newton</i> : expert evidence about the standard of clinical notes. <i>Journal of Law &amp; Medicine</i> , 2007, 15, 360-5.	0.0	0
71	Toward a treaty on safety and cost-effectiveness of pharmaceuticals and medical devices: enhancing an endangered global public good. <i>Globalization and Health</i> , 2006, 2, 5.	4.9	10
72	Policy challenges from the "White" Senate inquiry into workplace-related health impacts of toxic dusts and nanoparticles. <i>Australia and New Zealand Health Policy</i> , 2006, 3, 7.	2.2	3

#	ARTICLE	IF	CITATIONS
73	Public hospitals in China: privatisation, the demise of universal health care and the rise of patient-doctor violence. <i>Journal of Law &amp; Medicine</i> , 2006, 13, 465-70.	0.0	11
74	Flexner's ethical oversight reprised? Contemporary medical education and the health impacts of corporate globalisation. <i>Medical Education</i> , 2005, 39, 1066-1074.	2.1	5
75	Collaborative research trials: A strategy for fostering mental health protections in developing nations. <i>International Journal of Law and Psychiatry</i> , 2005, 28, 171-181.	0.9	6
76	Will international human rights subsume medical ethics? Intersections in the UNESCO Universal Bioethics Declaration. <i>Journal of Medical Ethics</i> , 2005, 31, 173-178.	1.8	46
77	Practical virtue ethics: healthcare whistleblowing and portable digital technology. <i>Journal of Medical Ethics</i> , 2005, 31, 612-618.	1.8	70
78	Coherence and healthcare whistle-blowing: A response to Parker. <i>Monash Bioethics Review</i> , 2005, 24, 47-49.	0.8	0
79	The UNESCO Bioethics Declaration – social responsibility – principle and cost-effectiveness price evaluations for essential medicines. <i>Monash Bioethics Review</i> , 2005, 24, 10-19.	0.8	6
80	Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy. <i>Globalization and Health</i> , 2005, 1, 15.	4.9	20
81	Fiduciary disclosure of medical mistakes: the duty to promptly notify patients of adverse health care events. <i>Journal of Law &amp; Medicine</i> , 2005, 12, 478-82.	0.0	5
82	The Messiha and Schiavo cases: third-party ethical and legal [corrected] interventions in futile care disputes. <i>Medical Journal of Australia</i> , 2005, 183, 261-3.	1.7	2
83	Supporting whistleblowers in academic medicine: training and respecting the courage of professional conscience. <i>Journal of Medical Ethics</i> , 2004, 30, 40-43.	1.8	44
84	Developing and teaching the virtue-ethics foundations of healthcare whistle blowing. <i>Monash Bioethics Review</i> , 2004, 23, 41-55.	0.8	25
85	Pharmaceuticals, intellectual property and free trade: the case of the US–Australia free trade agreement. <i>Prometheus</i> , 2004, 22, 243-257.	0.4	59
86	When silence threatens safety: lessons from the first Canberra Hospital neurosurgical inquiry. <i>Journal of Law &amp; Medicine</i> , 2004, 12, 112-8.	0.0	2
87	Atypical Antidepressants in Overdose. <i>Drug Safety</i> , 2003, 26, 539-551.	3.2	35
88	Normative role for medical humanities. <i>Lancet</i> , The, 2003, 362, 1859.	13.7	4
89	Of Consents And Consorts: Reporting Ethics, Law, And Human Rights In Rcts Involving Monitored Overdose Of Healthy Volunteers Pre And Post The –Consort–Guidelines. <i>Journal of Toxicology: Clinical Toxicology</i> , 2003, 41, 93-99.	1.5	14
90	Melatonin supplementation from early morning auto-urine drinking. <i>Medical Hypotheses</i> , 1991, 36, 195-199.	1.5	8

#	ARTICLE	IF	CITATIONS
91	Safety of Nanoparticles in Sunscreens. SSRN Electronic Journal, 0, , .	0.4	0
92	Innovation and insufficient evidence: the case for a WTOâ€™WHO Agreement on Health Technology Safety and Cost-Effectiveness Evaluation. , 0, , 209-232.		0
93	Emerging Technologies: Challenges for Health Care and Environmental Ethics and Rights in an Era of Globalisation. , 0, , 49-62.		0